Market Currents
Peregrine Pharmaceuticals' (PPHM) previously reported data for Phase II testing of its...
-
Monday, September 24, 2012, 7:39 AM ETPeregrine Pharmaceuticals' (PPHM) previously reported data for Phase II testing of its bavituximab drug is no longer reliable as the company has discovered major discrepancies between some patient sample test results and patient treatment code assignments. Shares remain halted. (PR)
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
This news story has 10 comments:
Expect it to hover in a trading range of $0.40 - $0.90...